Clinical and Translational Gastroenterology · 2021 · 12 citations · 29 references
MedicineHealth InformaticsBehavioral HealthBehavioral MedicineMental Health CareAnxiety DisordersBehavioral Health InformaticsBehavioral Health IntegrationCognitive Behavioral TherapyFunctional Gastrointestinal DisordersPsychosocial InterventionsCognitive Interventions For AnxietyFunctional Gastrointestinal SymptomsGastrointestinal Symptom BurdenGastrointestinal Symptom ManagementMood Symptom AssessmentPatient-reported Symptom InteractionsText Messaging CommunicationText Messaging Support
INTRODUCTION: Traditional cognitive behavioral interventions (CBIs) improve mood and gastrointestinal symptom severity in patients with functional gastrointestinal disorders (FGIDs) but face substantial barriers to implementation. Integrating behavioral health technology into medical clinic workflows could overcome these barriers. We evaluated the feasibility and impact of a coached digital CBI (dCBI) as a first-line intervention in a prospective cohort of emotionally distressed patients with FGID. METHODS: Patients with anxiety and/or depressive symptoms were offered a dCBI (an app called RxWell) during routine clinic visits. RxWell provides cognitive behavioral techniques enhanced by within-app text messaging with a health coach. Both gastroenterology and behavioral health-care providers electronically prescribed RxWell. We tracked patient interactions with RxWell, and patients completed anxiety (General Anxiety Disorder-7) and depression (Personal Health Questionniare Depression Scale) measures through the app. Our primary study outcome was the change in General Anxiety Disorder-7 and Personal Health Questionniare Depression Scale scores. RESULTS: Of 364 patients with FGID (mean age 43 years [SD 16 years]; 73.1% women) prescribed the dCBI, 48.4% enrolled (median use, 3 techniques [interquartile range 1-14]). About half of RxWell enrollees communicated with health coaches. The mean baseline anxiety score was 11.4 (SD 5.5), and the depression score was 11.5 (SD 6.1). RxWell users experienced improvements in anxiety (mean change 2.71 [t = 3.7, df = 58; P < 0.001]) and depression (mean change 2.9 [t = 4.2, df = 45; P < 0.001]) at 4 months. DISCUSSION: Patients with FGIDs and moderately severe anxiety and depressive symptoms are willing to use dCBI tools recommended by their providers. Our pilot data demonstrate that dCBI usage is associated with clinically and statistically significant mood symptom reductions.
29
A Brief Measure for Assessing Generalized Anxiety Disorder
Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams et al. · Archives of Internal Medicine · 2006 · 31.5K citations
Nursing, Psychiatry, Psychology +17
The PHQ-8 as a measure of current depression in the general population
Kurt Kroenke, Tara W. Strine, Robert L. Spitzer et al. · Journal of Affective Disorders · 2008 · 5.2K citations
Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction
Douglas A. Drossman, William L. Hasler · Gastroenterology · 2016 · 1.8K citations · Full text
Medicine, Neurology, Neuroscience +12